Massive Bio is launching a new webinar series with a roundtable discussion about AI’s role in precision oncology.
Massive Bio, which uses a proprietary artificial intelligence (AI)-based platform and concierge service to match cancer patients with clinical trials, will host a webinar titled “How is AI Driving Personalized Cancer Treatment?” This event, which is the first in a series and is open to the public, will be moderated by Arturo Loaiza-Bonilla, MD, chief medical officer and co-founder of Massive Bio. Panelists will include:
- Selin Kurnaz, PhD, chief executive officer (CEO) and co-founder of Massive Bio
- Çağatay Çulcuoğlu, chief technology officer (CTO), chief operating officer (COO), and co-founder of Massive Bio
- Oz Huner, chief product officer (CPO) at Massive Bio
During this event, participants will discuss how AI is revolutionizing the delivery of healthcare—with a focus on cancer care and management—by individualizing treatment regimens to achieve better outcomes. Kurnaz and her Massive Bio colleagues will explain how the company uses AI to rapidly and accurately identity clinical trials of innovative new oncology therapies for cancer patients, as well as describe new AI-based products the company is rolling out that will further improve cancer treatment. At the end of the discussion, there will be a Q&A period to allow attendees to ask any questions they may have about AI, personalized oncology treatments, customized clinical trial matching, and Massive Bio.
Future webinars hosted by Massive Bio will examine how clinical trials can benefit patients with hematologic cancers and the role of cancer biomarkers in oncology clinical trials and therapies. “How is AI Driving Personalized Cancer Treatment?” will be held on March 28, at 2:00 PM, and can be viewed on Massive Bio’s Facebook page. Click here to register and attend this free event.
